Clinical trial for polymer-subunit trivalent influenza vaccine Grippol plus reactogenicity assessment in 153 children aged 3–17 years old was conducted in the frames of post-registration studies. Prior to the vaccination the written informed agreement was signed by every participant’ parent. In post-vaccination period physical examination and thermometry was performed daily in post-immunization days 1–5, on days 21–28 and then on a monthly basis for 4 months. Study results demonstrated that Grippol plus possesses low reactogenicity and can be applied in pediatrics for immunization in accordance with National Immunization schedule.Key words: children, influenza, vaccination.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(4):37-41) В рамках пострегистрационного исследования выполнено клиническое наблюдение за реактогенностью полимерсубъединичной тривалентной гриппозной вакцины (Гриппол плюс) у 153 детей в возрасте 3–17 лет. Вакцинация проведена после получения информированного письменного согласия родителей. В поствакцинальном периоде осмотр и термометрия, а также контроль заболеваемости проводились ежедневно в первые 5 сут, на 21–28-е сутки и далее ежемесячно в течение 4 мес. Подтверждено, что вакцина является низкореактогенной и может быть применена в детской практике в рамках национального календаря прививок. Ключевые слова: дети, грипп, вакцинация.(Вопросы современной педиатрии. 2009;8(4):37-41)

Supervision over 200 children in the age of 18–42 months (64 healthy and 136 with allergic displays, defeats CNS, often ill, and also having in the anamnesis of reaction to previous introduction DTP or Infanriks), revaccination with Pentaxim. It is shown, that 77% from them had asymptomatic current, only in 1,5% of cases strong reactions with temperature above 38,6°С were observed. Local reactions were marked at 25,5%, essentially more often at children with an allergy, defeat CNS and often ill, than at healthy (7,8%), but did not one child was not adverse events. The estimation safety vaccines Pentaxim confirms expediency of application as 1 revaccination against perussis, diphtheria, tetanus, poliomyelitis and unitary vaccination against Haemophilus influenzae type B in children are more senior than year with a various state of health.

One hundred and seven children (45 girls and 62 boys) in the age of 20 months — 14 years old (mean 9,62±0,37) suffered from acute lymphoblast leukosis and solid tumors in history have been examined in the clinic of Research Institute of children infections of FMBA. The vaccination history was studied in all children and the titers of specific antibodies to measles and mumps viruses as well as immune status were determined. 83,8% and 85,4% of studied children had no protection against measles and mumps respectively or had low titers of anti- bodies. Immunological examination of these children conducted within 4 months after finishing of therapy revealed absence of immunodeficiency. It gave opportunities to vaccinate or revaccinate these children against mentioned in- fections. Fifty three children were immunized against measles and 47 — against mumps. Application of live vaccines was safe because majority of vaccinated against measles (81,1%) and mumps (82,9%) children had mild vaccination process. It was established that to increase immunological efficacy of vaccination using of polyoxidony during 5 days before vaccination and 5 days after vaccination is reasonable. (Infekci i immunitet, 2011, vol. 1, N 1, p. 85-91)

Clinical trial for polymer-subunit trivalent influenza vaccine Grippol plus reactogenicity assessment in 153 children aged 3–17 years old was conducted in the frames of post-registration studies. Prior to the vaccination the written informed agreement was signed by every participant’ parent. In post-vaccination period physical examination and thermometry was performed daily in post-immunization days 1–5, on days 21–28 and then on a monthly basis for 4 months. Study results demonstrated that Grippol plus possesses low reactogenicity and can be applied in pediatrics for immunization in accordance with National Immunization schedule. Key words: children, influenza, vaccination. ( Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(4): 37-41 )

THE LECTURE SHOWS THE MODERN STATE OF THE PERTUSSIS ISSUE AMONG THE CHILDREN. BASED ON THE ANALYSIS OF THE PRESENTED DATA, THE AUTHORS CONCLUDE THAT VACCINATION WITH THE FULL CELLULAR VACCINE IS RATHER SAFE; MOREOVER, IT PROTECTS THE INFANTS FROM THE SEVERE FORMS OF THE DISEASE AND LETHAL OUTCOMES. HOWEVER, THE FACT THAT THERE ARE CHILDREN WITH CONSTANT CONTRAINDICATIONS TO IMMUNIZATION WITH THE FULL CELLULAR VACCINE, THE CHANGE OF THE CIRCULATING B.PERTUSSIS SEROTYPES, MORBIDITY OF THE OLDER CHILDREN DUE TO THE LOSS OF THE POST-VACCINAL IMMUNITY DEFINE THE NECESSITY TO INTRODUCE REVACCINATION, AS WELL AS THEY ARE INDICATIONS TO THE WIDER IMPLEMENTATION OF THE NON-CELLULAR PERTUSSIS VACCINE.

THE RESEARCHERS OBSERVED 45 CHILDREN INOCULATED WITH THERUSSIAN DIVALENT VACCINE (MEASLES–PAROTIDITIS). 25 CHILDRENRECEIVED MINERAL AND VITAMIN COMPLEX «JUNGLE» FOR A MONTH SINCETHE DATE OF VACCINATION. THE APPLICATION OF «JUNGLE» MEDICATIONWAS EFFICIENT AND CONDUCED TO PROPHYLAXIS OF THE COMPLICATIONOF THE VACCINATION, PREVENTION OF THE INTERCURRENT DISEASESAMONG THE VACCINATED, AS WELL AS POSITIVELY AFFECTED THE INTENSITY OF THE SPECIAL ANTIBODY FORMATION BECAUSE OF ACTIVATION OF CELLULAR AND ANTIVIRAL MECHANISMS.KEY WORDS: VACCINATION, MEASLES, PAROTIDITIS, PREVENTION,MINERAL AND VITAMIN COMPLEX, CHILDREN.

The morbidity structure was analyzed in children vaccinated against epidemic parotitis in 1993-2002. Eight children (4 with serous meningitis and 4 with lesions of the salivary glands) underwent virologic and immunologic examinations. The molecular typing of the SH-gene fragment of the parotitis virus showed the process in 7 cases to be provoked by the vaccination strain. Presumedly, progressing vaccine-associated meningitis inhibits antibody formation. The total incidence of vaccine-associated meningitis was shown, according to Saint Petersburg data, to be not high, which testifies to a low reactogenicity of the Russian vaccine strain.